Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Drug Profile

Meningococcal vaccine groups A B C Y W-135 conjugate - GlaxoSmithKline

Alternative Names: GSK-3536819A; MenABCWY; Meningococcal ABCWY Vaccine; rMenB + MenACWY

Latest Information Update: 27 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 19 Dec 2018 GlaxoSmithKline completes a phase II/III trial in Meningococcal group A, B, C, Y, W-135 infections (In adolescents, In children, Prevention, In adults) in Czech Republic (IM) (NCT03587207)
  • 09 Jul 2018 Phase-II/III clinical trials in Meningococcal group A infections (In children, In adolescents, In adults, Prevention) in Czech Republic (IM) (NCT03587207)
  • 09 Jul 2018 Phase-II/III clinical trials in Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in Czech Republic (IM) (NCT03587207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top